Abstract: The present invention discloses polynucleotides which identify and encode DP119, DP444, DP810, DP685, WE474, DP160, RA977, or RA770 as well as novel functions for these proteins of the inventions. The invention provides for compositions for disorders associated with the expression of the proteins of the invention, such as for the treatment, alleviation and/or prevention of pancreatic dysfunction (for example diabetes, hyperglycemia, and impaired glucose tolerance), and related disorders, and other disease and disorders.

Abstract: The present invention discloses polynucleotides which identify and encode DP119, DP444, DP810, DP685, WE474, DP160, RA977, or RA770 as well as novel functions for these proteins of the inventions. The invention provides for compositions for disorders associated with the expression of the proteins of the invention, such as for the treatment, alleviation and/or prevention of pancreatic dysfunction (for example diabetes, hyperglycemia, and impaired glucose tolerance), and related disorders, and other disease and disorders.

Abstract: Provided herein are methods for the treatment of metabolism disorders by delivering a therapeutically effective amount of a modulator of a SOUP1 polypeptide. The invention also relates to a nucleic acid molecule encoding a polypeptide contributing to membrane stability and/or function of organelles.

Abstract: The present invention discloses polynucleotides which identify and encode DP119, DP444, DP810, DP685, WE474, DP160, RA977, or RA770 as well as novel functions for these proteins of the inventions. The invention provides for compositions for disorders associated with the expression of the proteins of the invention, such as for the treatment, alleviation and/or prevention of pancreatic dysfunction (for example diabetes, hyperglycemia, and impaired glucose tolerance), and related disorders, and other disease and disorders.

Abstract: The present invention discloses polynucleotides which identify and encode pD52 or pRA006 as well as novel functions for the D52 gene family (pD52) which are specifically expressed in the embryonic pancreatic epithelium, in islet cells of the pancreas, in adipocytes, and in intestinal crypt cells. The invention also discloses novel function for the RA006 gene family (pRA006) which are specifically expressed in a subset of islet cells of the pancreas, the eye, as well as the central and peripheral nervous system. The invention provides for compositions for disorders associated with the expression of pD52 or pRA006, such as for the treatment, alleviation and/or prevention of metabolic disorder or metabolic syndrome, such as pancreatic dysfunction (for example diabetes, hyperglycemia, and impaired glucose tolerance), obesity, adipositas, eating disorders (bulimia nervosa, anorexia nervosa), cachexia (wasting), and neurodegenerative disorders, and other diseases and disorders.